Literature DB >> 12417589

Proteolytic processing of the hepatitis B virus e antigen precursor. Cleavage at two furin consensus sequences.

Fabienne Messageot1, Samia Salhi, Patricia Eon, Jean-Michel Rossignol.   

Abstract

The Hepatitis B virus P22 protein is a nonstructural protein that is the precursor of the 17-kDa secreted e antigen (HBeAg). The mature HBeAg is obtained after the removal of the C-terminal region of P22, a process which involves a proprotein convertase. Our studies show first that the protease could cleave P22 at the C-terminal side of Arg(167) or Arg(154) and second, that the maturation process can be either done in one step or in two steps with the generation of a processing intermediate (P20). Our data also demonstrate that the removal of the P22 C terminus, which occurs mainly in the trans-Golgi network, can also be achieved after exocytosis. Keeping in mind this characteristic and the amino acid sequence of the cleavage sites, we concluded that furin is involved in the maturation of the HBeAg. In addition, we show that in our experimental system, the HBeAg is a 164-amino acid protein and not a 159-amino acid protein as previously reported.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12417589     DOI: 10.1074/jbc.M207634200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  The shed ectodomain of type XIII collagen affects cell behaviour in a matrix-dependent manner.

Authors:  Marja-Riitta Väisänen; Timo Väisänen; Taina Pihlajaniemi
Journal:  Biochem J       Date:  2004-06-15       Impact factor: 3.857

2.  In vitro and in vivo interactions between the hepatitis B virus protein P22 and the cellular protein gC1qR.

Authors:  S Lainé; A Thouard; J Derancourt; M Kress; D Sitterlin; J-M Rossignol
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

3.  Hepatitis B e Antigen Inhibits NF-κB Activity by Interrupting K63-Linked Ubiquitination of NEMO.

Authors:  Yuan Wang; Lei Cui; Guifang Yang; Jianbo Zhan; Liang Guo; Yu Chen; Chengpeng Fan; Dan Liu; Deyin Guo
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

4.  New perspectives on the hepatitis B virus life cycle in the human liver.

Authors:  Peter A Revill; Stephen A Locarnini
Journal:  J Clin Invest       Date:  2016-02-22       Impact factor: 14.808

5.  Heterologous prime-boost immunization with vesiculovirus-based vectors expressing HBV Core antigen induces CD8+ T cell responses in naïve and persistently infected mice and protects from challenge.

Authors:  Carolina Chiale; Safiehkhatoon Moshkani; John K Rose; Michael D Robek
Journal:  Antiviral Res       Date:  2019-05-30       Impact factor: 5.970

6.  Chimeric rabbit/human Fab antibodies against the hepatitis Be-antigen and their potential applications in assays, characterization, and therapy.

Authors:  Xiaolei Zhuang; Norman R Watts; Ira W Palmer; Joshua D Kaufman; Altaira D Dearborn; Joni L Trenbeath; Elif Eren; Alasdair C Steven; Christoph Rader; Paul T Wingfield
Journal:  J Biol Chem       Date:  2017-08-23       Impact factor: 5.157

Review 7.  Overview of hepatitis B viral replication and genetic variability.

Authors:  Shuping Tong; Peter Revill
Journal:  J Hepatol       Date:  2016-04       Impact factor: 25.083

Review 8.  Hepatitis B virus: virology, molecular biology, life cycle and intrahepatic spread.

Authors:  P Karayiannis
Journal:  Hepatol Int       Date:  2017-11-02       Impact factor: 6.047

9.  Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators.

Authors:  Dawei Cai; Xiaohe Wang; Ran Yan; Richeng Mao; Yuanjie Liu; Changhua Ji; Andrea Cuconati; Haitao Guo
Journal:  Antiviral Res       Date:  2016-05-13       Impact factor: 5.970

10.  Downregulation of interleukin-18-mediated cell signaling and interferon gamma expression by the hepatitis B virus e antigen.

Authors:  S Jegaskanda; S H Ahn; N Skinner; A J Thompson; T Ngyuen; J Holmes; R De Rose; M Navis; W R Winnall; M Kramski; G Bernardi; J Bayliss; D Colledge; V Sozzi; K Visvanathan; S A Locarnini; S J Kent; P A Revill
Journal:  J Virol       Date:  2014-05-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.